Calcitonin gene-related peptide is commonly shortened to CGRP. The expanded name supplies an important clue to its discovery, but it can also cause confusion: CGRP is not another spelling of calcitonin, and the abbreviation does not specify its alpha or beta form. The receptor used to study it also needs more definition than a single gene name.
What “gene-related” means here
Rosenfeld and colleagues’ 1983 paper described different RNA processing in neural tissue and thyroid C cells. The resulting messages encoded precursors for CGRP and calcitonin respectively, providing a route from one gene to distinct peptide products.Rosenfeld and colleagues — Tissue-specific processing and CGRP (opens in a new tab)
This is a relationship between how the products are encoded and processed. It does not make the final molecules chemically interchangeable.
A reader encountering “calcitonin/CGRP gene” should therefore check whether the experiment measured a transcript, a precursor or one of the mature products. A gene-level change cannot be assumed to quantify both mature peptides equally.
Alpha and beta identify distinct sequences
Steenbergh and colleagues’ 1985 human gene study reported a second CGRP sequence, differing from the previously known peptide at three of its 37 residues. Current IUPHAR nomenclature distinguishes alpha-CGRP from beta-CGRP and identifies their separate gene origins.Steenbergh and colleagues — A second human calcitonin/CGRP gene (opens in a new tab)IUPHAR/BPS — Calcitonin-family receptor introduction (opens in a new tab)
The curated human alpha-CGRP structure has a disulfide between cysteines 2 and 7 and an amidated terminal phenylalanine. These details belong alongside the sequence when defining that reference molecule.IUPHAR/BPS — Human alpha-CGRP structure (opens in a new tab)
| Field | Why it matters |
|---|---|
| Alpha or beta | Distinguishes closely related sequences |
| Species | Keeps the sequence reference explicit |
| Residue interval | Separates intact peptide from a named fragment |
| Bridge and terminus | Records chemistry missing from a bare letter string |
A comparison can be scientifically useful even when two forms behave similarly in the chosen assay. Similarity in that result should be reported as a result, rather than used to erase the identity distinction.
Why RAMP1 belongs in the receptor description
McLatchie and colleagues’ 1998 experiments showed that receptor-activity-modifying proteins, or RAMPs, altered transport and ligand recognition of calcitonin receptor-like receptor. With RAMP1, the system displayed CGRP receptor characteristics; with RAMP2, it displayed adrenomedullin receptor characteristics.McLatchie and colleagues — RAMPs and receptor ligand specificity (opens in a new tab)
The finding makes the accessory-protein context part of the experimental identity. Listing only the core receptor can leave a crucial part of the ligand-recognition system unspecified.
This does not mean that RAMP1 is itself the peptide ligand or that it should be added to a CGRP sequence. Ligand composition and receptor-complex composition are separate descriptions on opposite sides of the interaction.
When evaluating a cell study, look for which receptor components were introduced or measured. That information is more informative than a general statement that the cells were “CGRP responsive”.
Read the intervention direction correctly
CGRP research can involve measuring the peptide, exposing a system to it, blocking its interaction, or changing receptor expression. Those are different interventions and need separate rows in an evidence summary.
A response to blockade cannot simply be inverted into a recommendation to supply the peptide. Nor does a change in circulating immunoreactivity identify the precise source tissue without additional evidence.
For a clear account, start each claim with the named molecular form and the action taken. Follow with the model, measured outcome and comparator. This makes an endogenous signalling study legible without borrowing conclusions from unrelated treatment studies.
The purpose of this reference is molecular orientation. Drug comparisons and clinical treatment choices require their own current evidence and are outside the identity question addressed here.
Sources and further detail
- Rosenfeld and colleagues — Tissue-specific processing and CGRP (opens in a new tab)
Original 1983 abstract read, retaining distinct mature products rather than treating the gene label as chemical equivalence.
- Steenbergh and colleagues — A second human calcitonin/CGRP gene (opens in a new tab)
Complete original abstract read for the human sequence comparison and 37-residue count.
- IUPHAR/BPS — Calcitonin-family receptor introduction (opens in a new tab)
CGRP nomenclature and separate gene origins checked; the broader clinical discussion is not reproduced.
- IUPHAR/BPS — Human alpha-CGRP structure (opens in a new tab)
Sequence and modification fields read, specifically the cysteine 2–7 bridge and terminal amide.
- McLatchie and colleagues — RAMPs and receptor ligand specificity (opens in a new tab)
Original 1998 abstract read for RAMP-dependent transport and the RAMP1/RAMP2 comparison.
Sources checked 19 September 2026. Worked examples are illustrative unless a supplied report is explicitly identified. This article has not undergone independent scientific peer review.